16681-73-5 Usage
Uses
Used in Pharmaceutical Industry:
3-bromo-4-methyl-1,2,4-triazole is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 3-bromo-4-methyl-1,2,4-triazole is employed as an intermediate in the production of agrochemicals, aiding in the creation of compounds that enhance crop protection and yield.
Used in Organic Synthesis:
3-bromo-4-methyl-1,2,4-triazole is used as a building block in organic synthesis, facilitating the construction of complex organic molecules and contributing to the advancement of chemical research and development.
Used in Photoactive Material Production:
3-bromo-4-methyl-1,2,4-triazole is utilized in the production of photoactive materials, where its unique properties contribute to the development of materials with specific light-sensitive characteristics, applicable in various technological applications.
Used in Bioactive Compound Synthesis:
3-bromo-4-methyl-1,2,4-triazole is considered a potential starting material for the synthesis of bioactive compounds, owing to its distinctive structure and reactivity, which can lead to the discovery of new bioactive substances with potential applications in medicine and other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 16681-73-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,6,8 and 1 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 16681-73:
(7*1)+(6*6)+(5*6)+(4*8)+(3*1)+(2*7)+(1*3)=125
125 % 10 = 5
So 16681-73-5 is a valid CAS Registry Number.
InChI:InChI=1/C3H4BrN3/c1-7-2-5-6-3(7)4/h2H,1H3
16681-73-5Relevant academic research and scientific papers
Novel small molecule bradykinin B2 receptor antagonists
Gibson, Christoph,Schnatbaum, Karsten,Pfeifer, Jochen R.,Locardi, Elsa,Paschke, Matthias,Reimer, Ulf,Richter, Uwe,Scharn, Dirk,Faussner, Alexander,Tradler, Thomas
supporting information; experimental part, p. 4370 - 4379 (2010/02/28)
Blockade of the bradykinin B2 receptor provides therapeutic benefit in hereditary angioedema (HAE) and potentially in many other diseases. Herein, we describe the development of highly potent B2 receptor antagonists with a molecular weight of approximately 500 g/mol. First, known quinoline-based B2 receptor antagonists were stripped down to their shared core motif 53, which turned out to be the minimum pharmacophore. Targeted modifications of 53 resulted in the highly water-soluble lead compound 8a. Extensive exploration of its structure-activity relationship resulted in a series of highly potent B2 receptor antagonists, featuring a hydrogen bond accepting functionality, which presumably interacts with the side chain of Asn-107 of the B2 receptor. Optimization of the microsomal stability and cytochrome P450 inhibition eventually led to the discovery of the highly potent and orally available B2 receptor antagonist 52e (JSM10292), which showed the best overall properties.
